Federal Circuit denies further term extensions to shoulder surgery patentee
09-02-2021
AbbVie and Amgen settle Humira clash
29-09-2017
AbbVie Humira patent invalidated by PTAB
19-05-2017
jansucko / iStockphoto.com
Yesterday, the US Court of Appeals for the Federal Circuit backed a lower court’s decision to dismiss a declaratory judgment lawsuit filed by AbbVie over its drug Humira (adalimumab).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
AbbVie, licence, MedImmune, patent, Humira, licence disagreement, patent invalidity, US Court of Appeals for the Federal Circuit
